source
- STAT+: Supreme Court rejects challenge to Medicare drug price negotiationThe rejection may make the pharma firms remaining lawsuits more difficult.STAT · 3mo ago↗ source
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much moreThe question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart, pitting peers and partners against one anotherSTAT · 3mo ago↗ source
- Regeneron immunotherapy combo comes up short in melanoma trialA two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…BioPharma Dive · 3mo ago